Biotech research, immunology innovation, and clinical development by Climb Bio
Climb Bio, Inc. advances rare kidney disease collaboration with patient-centered approach
Climb Bio, Inc. has reaffirmed its commitment to advancing research and collaborations within the rare kidney disease community following its participation at the NephCure Patient Summit. The ...
NephCure Patient and Youth Summits partnership expands support for rare kidney disease patients
Climb Bio, Inc. announced its sponsorship of the NephCure Patient and Youth Summits, aiming to bring patients, caregivers, researchers, and advocates together to foster collaboration and knowledge ...
Climb Bio, Inc. reports initial Phase 1b data show robust B cell depletion in ITP trial
Climb Bio, Inc. has announced initial results from its Phase 1b clinical trial, revealing that Budoprutug achieved on-target clinical activity in immune thrombocytopenia (ITP). The data, ...
Jefferies event spotlights Climb Bio, Inc. plan for autoimmune research
Climb Bio, Inc. is set to participate in a fireside chat with Jefferies later today, providing an opportunity to share insights into the company's ongoing work in immunology and autoimmune ...
Climb Bio, Inc. unveils initial safety and platelet data from Phase 1b/2a budoprutug trial in ITP
Climb Bio, Inc. announced new safety, B-cell depletion, and platelet data from the low dose cohort of its ongoing Phase 1b/2a trial of budoprutug in previously treated patients with immune ...
Climb Bio, Inc. drives new focus on APRIL-targeted B cell therapies at Dallas workshop
Climb Bio, Inc. is advancing B cell-directed therapies in the treatment of IgA nephropathy (IgAN), signaling growing momentum for approaches targeting the APRIL protein. At the National Kidney ...
Climb Bio, Inc. participates in HC Wainwright fireside chat to outline strategic direction
Climb Bio, Inc. took part in a fireside chat hosted by HC Wainwright earlier today. The session provided insights into the company’s ongoing initiatives and future direction, with a particular ...
Budoprutug potential in CD19 antibody therapy spotlighted by Climb Bio, Inc.
Climb Bio, Inc. will hold a live webcast next week featuring company leadership and Dr. David Jayne to discuss budoprutug, its investigational monoclonal antibody targeting CD19, and the broader ...
Climb Bio, Inc. joins The Future of Clinical Trial Design in IgA nephropathy
Climb Bio, Inc. participated in The Future of Clinical Trial Design in IgA Nephropathy event hosted by the National Kidney Foundation last week. The company expressed its commitment to promoting ...
Climb Bio, Inc. backs scientific collaboration on innovative trial design in nephrology
Climb Bio, Inc. announced its sponsorship and participation in The Future of Clinical Trial Design in IgA Nephropathy, a scientific workshop organized by the National Kidney Foundation. The ...
Climb Bio, Inc. to hold live R and D webcast on Budoprutug and CD19 opportunity
Climb Bio, Inc. will host a live webcast as part of its R and D Spotlight Series on May 5 at 8:00 AM. The session will feature company leadership alongside Dr. David Jayne, focusing on Budoprutug ...
